key: cord-0820508-uzbjzxse
authors: Khorramdelazad, Hossein; Kazemi, Mohammad Hossein; Azimi, Maryam; Aghamajidi, Azin; Mehrabadi, Ali Zarezadeh; Shahba, Faezeh; Aghamohammadi, Nazanin; Falak, Reza; Faraji, Fatemeh; Jafari, Reza
title: Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019
date: 2022-05-23
journal: Eur J Pharmacol
DOI: 10.1016/j.ejphar.2022.175051
sha: 4f3a27b801909601b4a48fd2d92d4bcf481781b6
doc_id: 820508
cord_uid: uzbjzxse

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation.

. COVID-19 was the greatest global health challenge and crisis since the influenza pandemic of 1918 (Cascella et al., 2021) . The first case of COVID-19 was reported in Wuhan, China, in late December 2019 and then spread rapidly around the world (Khorramdelazad et al., 2021) . Despite widespread vaccination in numerous countries, the new waves of COVID-19 are still catastrophically affecting the health, livelihood, and economy of the world's population (Nesteruk, 2020) .

Type-I interferons (IFN-Is), including IFN-Iα and IFN-Iβ, as a distinct class of cytokines, are at the forefront of immunological defense against viruses (Schreiber, 2020) . Moreover, these interferons (IFNs) are commonly involved in inflammatory responses, immune system regulation, tumor cell recognition, and functions of T lymphocytes (Lee and Shin, 2020) .

Based on the available evidence and past pandemic experiences, the administration of IFN-Is as an antiviral drug against SARS and Ebola showed a promising future (Konde et al., 2017; Loutfy et al., 2003; Schreiber, 2020) . In this context, it has been revealed that IFN-Is can exert their effects in both autocrine and paracrine manners, inducing expression of the interferon-stimulated genes (ISGs) that triggers antiviral response against infected host cells.

It has been disclosed that similar to numerous viruses, SARS-CoV-2 is able to escape the antiviral immune responses, including IFN-I-mediated antiviral episodes (Blanco-Melo et al., 2020) . Evaluation of SARS-CoV-2 infected individuals showed that virus-infected bronchial epithelial cells are responsible for the secretion of IFN-Is. However, IFN-I-dependent antiviral responses do not have adequate efficacy to control the viral infection, which may be due to escape mechanisms of the virus .

The presence of anti-IFN-I autoantibodies in some patients is another challenge in COVID-19 patients . These autoantibodies can neutralize IFN-Is in-vitro and in-J o u r n a l P r e -p r o o f vivo, and despite 13 different subtypes of IFN-α, autoantibodies against IFN-α2 is more frequently detectable in the bloodstream of COVID-19 patients ).

It appears that IFN-Is have a vital role in controlling SARS-CoV-2 infection. Moreover, during the initial days of the infection, it was believed that impaired IFN-I-dependent immune responses could lead to increased virus replication, which ultimately leads to the increased production and secretion of inflammatory cytokines and dysregulated pulmonary and systemic inflammation .

This review summarizes and describes the key roles of IFN-Is in the immunopathogenesis of COIVD-19 patients, as well as the importance of anti-IFN-I autoantibodies in the spread of SARS-CoV-2 infection and the subsequent excessive inflammation.

IFN-Is are a group of widely expressed cytokines produced and released by immune and nonimmune host cells as the first line of defense against viral infection. In a typical setting, a virus-infected cell releases interferons, causing nearby cells to intensify their antiviral defense (Ivashkiv and Donlin, 2014; Trinchieri, 2010) . Human interferons have been classified into three major types, mainly based on the characteristics of their signaling receptors (De Weerd and Nguyen, 2012; Pestka et al., 2004) . Genes encoding IFN-Is are located on chromosome 9 in humans and on chromosome 4 in mice (Capobianchi et al., 2015; de Padilla and Niewold, 2016) .

The human IFN-Is family encompasses 12 partially homologous IFN-α subtypes , IFN-β, and several single-gene products, including IFN-ɛ, IFN-τ, IFN-κ, IFN-ω, IFN-δ and IFN-ζ which are not welldefined, yet. IFN-δ and IFN-τ have been described in pig and cattle, respectively, and do not have a human homolog (Walter, 2020) .

Production of IFN-Is is initiated following the binding of pathogen-associated molecular patterns (PAMPs) to different host pattern recognition receptors (PRRs). The PRRs could be found in various parts of cells, including cell membrane, or within intracellular compartments (McNab et al., 2015; Zahid et al., 2020) . IFN-I production and signaling pathways are shown in Figure 1 .

The main intercellular receptors that recognize viral products such as RNA fragments are the retinoic acid-inducible gene I (RIG-I; also termed as DExD/H-Box Helicase 58 or DDX58) and melanoma differentiation-associated gene 5 (MDA5) (Goubau et al., 2013; Zahid et al., 2020) . The ligation of PAMPs to the mentioned receptors mediates distinct signaling pathways by stimulating the IFN-α/β encoding genes (Platanias, 2005) .

In a unique pathway, the RIG-I and MDA5 employ the adaptor mitochondrial antiviral signaling proteins (MAVs) and activate kinases including IκB kinase-ε (IKKε) and TANKbinding kinase 1 (TBK1) (Paludan and Bowie, 2013) .

Interestingly, cytosolic nucleotide oligomerization domain-like receptors (NLRs, also called NACHT, LRR, and PYD domain proteins) are expressed in numerous cell types and bind to nucleic acids, resulting in the production and release of IFN-α/β (Kuenzel et al., 2010) .

Other DNA-binding receptors involved in IFN-Is production are DNA-dependent activator of IFN-regulatory factors (DAI or ZBP1), cytosolic GAMP synthase, and DExD/H box helicase.

In addition to the mentioned receptors, several toll-like receptors (TLRs) can activate IFN-α/β production pathways (Moynagh, 2005; Takeuchi et al., 2004) .

All mentioned signals, through different pathways, converge on a key transcription factor named IFN-regulatory factor (IRF). In fact, IFN-α/β gene transcription is mainly induced via IRF3, leading to the transcription of IRF7, which makes a positive feedback loop, triggering J o u r n a l P r e -p r o o f the involvement of other IFNα-encoding genes (Moynagh, 2005; Tamura et al., 2008) . All IFN-Is could bind to a common cell-surface heterodimeric receptor, known as IFN-α/β receptor (IFNAR) as the inducer of downstream cascades (Ivashkiv and Donlin, 2014) .

Receptor-associated protein tyrosine kinases (TYKs) including Janus kinase and signal transducer and activator of transcription (JAK/STAT) are the classical mediators of the IFNα/β signaling pathway. The binding of IFN-α/β to IFNAR results in the activation of JAK1 and TYK2, which can phosphorylate a couple of cytosolic transcription factors, especially STAT1 and STAT2. Homodimers and heterodimers of STAT1 and STAT2 are translocated to the nucleus and attach to IRF9 and forms IFN-stimulated gene factor 3 (ISGF3), which is regarded as an important transcriptional complex for binding to IFN-stimulated response elements (ISREs) (Ivashkiv and Donlin, 2014) . Upon recognizing the ISREs in the ISG promoters, ISGF3 initiates transcription of ISREs, which creates an antiviral state in the cell (Ivashkiv and Donlin, 2014; Platanias, 2005) .

Moreover, in mammals, following the binding of IFNα/β to IFNAR, the phosphoinositide 3-kinases (PI3K) can be activated, which is the target of the rapamycin (mTOR) pathway and multiple mitogen-activated protein kinase (MAPK) pathways (Platanias, 2005) . Briefly, phosphorylation of the PI3K, downstream of JAKs, can be induced by several IFN-Is, including IFN-α, IFN-β, and IFN-ω, resulting in the activation of the p110 catalytic subunit of PI3K. Finally, PI3K can activate various downstream signaling cascades with diverse biological effects (Platanias, 2005) .

Similar to the MAPK pathways, the p38-signaling pathway has a vital role in generating IFNmediated signals. It was shown that p38α is phosphorylated by IFN-α/β-mediated mechanisms, independent of STAT-mediated pathways and ISRE binding. Moreover, it has J o u r n a l P r e -p r o o f been revealed that p38 is also needed for the transcription of the IFN-α/β-driven genes through GAS elements (Platanias, 2005) .

Regarding the diversity of IFN-α/β-mediated signaling, widespread biological effects of IFNα/β are conceivable; therefore, besides activation of specific antiviral genes, they can induce various genes, including pro-and anti-apoptotic molecules (Ivashkiv and Donlin, 2014) .

Indeed, in viral infections, protective, immunosuppressive, or immunopathological effects of IFN-Is are determined by the characteristics and context of the pathogen interaction with host cells and exposure timeline with IFN-Is (McNab et al., 2015) . For example, IFN-Is contribute to inflammation by recruiting immune cells (Figure 2a ), which could have beneficial or harmful outcomes for the host, based on immunosuppressive or tissue-damaging effects (da Silva et al., 2021; McNab et al., 2015) .

Dendritic cells (DCs), mainly plasmacytoid dendritic cells (pDCs), and macrophages could recognize viral nucleic acids and proteins by their PRRs, inducing the production and release of IFN-Is (Ali et al., 2019; De Weerd and Nguyen, 2012; Ng et al., 2019) . IFN-Is upregulate MHC-I expression in multiple cell lineages and enhance antigen presentation, especially in DCs (Murira and Lamarre, 2016; Teijaro, 2016) . Exposure of immature DC to IFN-I can result in the upregulation of co-stimulatory molecules, enhanced antigen presentation, increased chemokine and cytokine production, and stimulation of B and T cells (De Weerd and Nguyen, 2012; McNab et al., 2015) . Viral infections also enhance TLR expression and production of IFN-Is in neutrophils. Interestingly, IFN-Is cause a positive feedback loop in the formation of neutrophil extracellular traps (NETs) following the binding of viral DNA to TLR9 and enhancing IFN-I production (Stegelmeier et al., 2021) .

J o u r n a l P r e -p r o o f IFN-Is also enhance natural killer (NK) cell recruitment, cytotoxicity, survival, and functions and protect antiviral CD8 + T cells from the lytic properties of NK cells (Teijaro, 2016) . In this regard, Madera et al. showed that expansion and memory cell formation of Ly49H + NK cells are impaired in IFNAR -/or STAT1 -/-(as IFNAR downstream signaling molecule) mice following cytomegalovirus (CMV) infection. In addition, IFNAR -/-NK cells were more susceptible to apoptosis than normal NK cells, and the expression of group 2-member D (NKG2D) ligands improved during CMV infection. Eventually, these NK cells demonstrated decreased protection against CMV (Madera et al., 2016) . Therefore IFN-I stimulatory or inhibitory effects on IFN-γ production by NK cells depend on the ratio of STAT molecules; for example, increased STAT4 signaling induces IFN-γ production by NK cells (McNab et al., 2015) .

IFN-Is play a pivotal role in the antiviral function of adaptive immune cells (Figure 2b ). They promote DC maturation, upregulate antigen-presentation of APCs, and orchestrate the adaptive immune responses (Mantlo et al., 2020; Ng et al., 2019) . B cells are involved in humoral immune responses against viral infection through the production of neutralizing antibodies. In this context, IFN-Is could stimulate B cell activation, function, and antibody class switching by altering the expression of transcription factors (McNab et al., 2015) . Furthermore, following IFN-I-induced maturation and activation of DCs, they release various cytokines and chemokines such as IL-12, which are required for T helper-1 (Th1) differentiation and antiviral activities (McNab et al., 2015) . IFN-Is also have different stimulatory impacts on the functionality and characteristics of CD8 + T cells, including the expression level of co-stimulatory molecules, proliferation, survival, and cytotoxicity (Crow and Ronnblom, 2019; Teijaro, 2016) .

J o u r n a l P r e -p r o o f Similar to NK cells, the concentration of IFN-Is and the duration of exposure of CD8 + T cells to IFN-Is can affect the immune response via STAT-mediated signaling pathways (De Weerd and Nguyen, 2012; Teijaro, 2016) . However, STAT molecules may demonstrate both positive and negative impacts on IFN-Is production. For instance, in a STAT1 dominant status, such as an increased ratio of STAT1/STAT4 IFN-γ production is inhibited (McNab et al., 2015) . It has been revealed that the MX1 and MX2 genes are activated in defense against various RNA viruses and provide antiviral effects. In addition, the expression of MX1 and MX2 genes in COVID-19 patients are increased in direct proportion to viral load, and their expression is inversely related to the age of the patients. Considering the lowered expression of MX proteins in elderly patients, it can be hypothesized that the high severity rate of disease in elderly patients is probably associated with decreased expression of MX antiviral proteins (Bizzotto et al., 2020; Verhelst et al., 2012; Zav'yalov et al., 2019) .

According to previous investigations, coronavirus members' susceptibility to IFN-Is is significantly different, but there is no explanation for these findings (Kindler et al., 2016) .

inhibiting the virus access to vital parts of the targeted cells (Anafu et al., 2013; Brass et al., 2009; Huang et al., 2006) . IFITM1 is found mainly in cellular plasma membranes, and IFITM2 and IFITM3 proteins are principally localized in endo-lysosomal membranes of the cells (Bailey et al., 2014) .

The IFITMs play an essential role in defense against many viruses and can be considered one of the main mechanisms of innate immunity and its connection to adaptive immunity (Prelli Bozzo et al., 2021) . Nevertheless, some viruses employ the advantages of these proteins.

According to the study by Xuesen Zhao et al., the HCoV-OC43 virus, one of the common cold agents, responds oppositely to IFN-Is, and these cytokines increase the possibility of cell infection caused by this virus. An explanation for this contradiction could be traced back to IFITM2 and IFITM3, which can facilitate virus entry into the target cells (Zhao et al., 2014) .

The S protein of SARS-CoV-1 mediates virus entry, and similar to influenza A and flaviviruses, this virus requires an acidic pH to enter the target cells (Harrison, 2008; Huang et al., 2011) . SARS-COV-1 also requires cathepsin-L to enter the cell by fusion, and IFITM1, 2, and 3 could prevent the entry. The IFITMs can interfere with endosomal trafficking or access to the late endosomal compartment (Huang et al., 2006; Huang et al., 2011) . MERS and HCoV-229E, two other coronaviruses, use a similar mechanism to SARS-CoV-1 for entrance to the target cell, and studies show that IFITMs can also prevent the entry of these viruses into the target cells (Bertram et al., 2013; Wrensch et al., 2014) . SARS-CoV-2, another member of the coronavirus family, is also sensitive to the IFITMs; however, this susceptibility has been moderately reduced compared to SARS-COV-1 due to polybasic cleavage sites that allow the virus to enter the target cells in a pH-independent manner, resulting in more virus transmission and replication (Winstone et al., 2021) . (Schreiber, 2020) . However, the innate immune system cannot overcome this virus, most likely due to the SARS-CoV-2 inhibitory mechanisms interfering with IFN-I production. For example, both SARS-CoV-1 and SARS-CoV-2 use papain-like proteases (PLpros) to attenuate IFN-I-mediated responses and suppress innate immunity responses (Daczkowski et al., 2017; Schreiber, 2020; Shin et al., 2020) .

The history of therapeutic and prophylactic use of IFN-I in coronavirus infections dates back to 1983 when Higgins et al. showed that intranasal IFN-α2 administration before and after challenge with coronavirus could reduce virus replication and consequently diminish the incidence and severity of disease in patients (Higgins et al., 1983) . In SARS and MERS epidemics, IFN-Is were used along with other treatments to reduce the severity of the disease and to accelerate the recovery process (Loutfy et al., 2003; R Strayer et al., 2014) . These promising outcomes encouraged the scientists to use IFN-Is to treat this family's new unwelcome child, SARS-CoV-2.

Probably, a primary mechanism used by SARS-CoV-2 to bypass the innate immune responses is through inhibiting the production of ISGs and IFN-Is, especially IFN-β.

Therefore, the IFN-I mediated responses are crucial in antiviral defense, and it appears that they are impaired in COVID-19 patients . IFN-I-deficient animal models have also demonstrated the critical role of IFN-I in disease recovery (Sun et al., 2020) . These findings justified the administration of recombinant external IFN-Is as a treatment for patients with COVID-19, aiming to replace the patient's reduced endogenous IFN-I (Lokugamage et al., 2020; Schreiber, 2020) . Furthermore, IFN-I administration is J o u r n a l P r e -p r o o f imperative in elder COVID-19 patients that naturally have diminished IFN-I responses (Aricò et al., 2020) .

Numerous reduced the viral load, and diminished the rate of critically ill patients (Hung et al., 2020) .

Probably, the subcutaneous injection elicits a systemic response of IFN-Is along with their antiviral functions (Schreiber, 2020) .

Because SARS-CoV-2 has tropism to the respiratory tract, numerous clinical trials have used this route of administration to maximize the IFN-Is prophylactic and therapeutic effects Monk et al., 2021; Wang et al., 2020; Zhou et al., 2020b) . The history of intranasal administration of IFN-I to fight respiratory system infections goes back to the 1970s which aimed to control the replication of rhinoviruses and influenza (Merigan et al., 1973) . A study in China on 2,944 hospital staff found that IFN-α1 nasal drops were 100%

protective against SARS-CoV-2 infection without serious side effects (Meng et al., 2020) .

Consequently, it seems that this method could be helpful to hinder infection in high-risk individuals during pandemics. However, intranasal administration may unintendedly deliver J o u r n a l P r e -p r o o f the substances to the central nervous system (CNS) and result in further neurotoxicity (Thorne et al., 2008) . Therefore, some prefer to consider the oral mucosa as the administration route due to rapid absorption of the substances, eliciting mucosal immunity, and less concern about neurotoxicity. It has been shown that the oral administration of lowdose IFN-α promoted immunity against respiratory infections and reduced disease severity (Bennett et al., 2013) . Other advantages of mucosal administration are ease of the process, low toxicity, reduced local and systemic effects, and prevention of the entrance of the virus through the entry sites (Aricò et al., 2020) .

Another method for mucosal IFN-I administration is using a respiratory nebulizer (Monk et al., 2021) . In this method, IFN-I is delivered directly into the infected respiratory epithelial cells with SARS-CoV-2 and replaces the missing endogenous IFN-I (Monk et al., 2021; Zhou et al., 2020b) . In a clinical trial (NCT04385095) on 101 patients, the use of SNG001 (IFNβ1a suitable for nebulization) reduced the severity of disease or mortality rate by 79% and increased the chance of recovery by 100% compared to the controls. In this study, the most frequently reported adverse event was headache (Monk et al., 2021) . In another study, respiratory administration of IFN-α2b alone or in combination with arbidol (Umifenovir) also diminished the plasma levels of inflammatory mediators such as IL-6 and C-reactive protein (CRP) as well as the presence of the virus in the upper respiratory tract. In this trial, adverse effects of the treatment had not been reported (Zhou et al., 2020a) . However, IFN nebulization is currently not applied during standard treatment of COVID-19, because there are some data regarding the risks of transmitting the viral infection by nebulization (Mary et al., 2020; Sethi et al., 2020) .

On the other hand, clinical trials investigating effects of recombinant IFN-γ (Type II IFN) and IFN-λ (Type III IFN could prevent clinical deterioration and shorten duration of viral shedding (Feld et al., 2021) .

Despite obtaining satisfactory outcomes, there are still several contradictions and questions that limit the administration of IFN-Is in patients with COVID-19. For instance, some studies have reported a negative association between late IFN-I therapy and clinical improvement in COVID-19 . Another important ambiguity regarding the treatment of COVID-19 using IFN-I is to determine the appropriate time to start the treatment (Aricò et al., 2020; Wang et al., 2020) .

A retrospective study compared the efficacy of nebulized IFN-α2 in the initial and advanced phases of COVID-19 and found that early IFN-α2 therapy significantly reduced patient mortality. However, IFN-α2 administration in advanced stages of the disease could not improve the treatment procedure and even delayed the recovery and increased the mortality rate . Other studies emphasized early initiation of IFN-I treatment and

proposed that the ideal administration time could be within the early five days after J o u r n a l P r e -p r o o f symptoms onset and could be extended up to maximum ten days after onset of the symptoms (Aricò et al., 2020; Hung et al., 2020; Wang et al., 2020) . However, these studies warned about the use of IFN-I treatment in advanced stages of the disease, regarding high mortality due to hyper-inflammation and cytokine storm in late stages (Aricò et al., 2020; Wang et al., 2020) . Given that the main therapeutic mechanism of IFN-I is preventing the virus replication, it seems logical that the optimal time of IFN-I usage is the early stages of the disease when the virus is replicating. IFN-I administration at the early stages of the disease can bridge innate and adaptive immunity by stimulating humoral and cellular responses (Aricò et al., 2020) . In addition to antiviral functions, IFN-Is also have pro-inflammatory properties. Therefore, if patients enter the hyper-inflammatory phase in which cytokine storm occurs, IFN-I intensifies secretion of the inflammatory cytokines, exacerbating the inflammation and increasing the mortality risk (Aricò et al., 2020) . Some studies believe that the severe IFN-I response is one of the main suspects for hyper-inflammatory responses in COVID-19 patients (Wilk et al., 2020; Zhou et al., 2020b) . Normally, high levels of tumor necrosis factor (TNF) induce tolerance to TLR signaling in monocytes to prevent more severe inflammation (Park et al., 2017) . High levels of IFN-Is abrogate the TLR tolerance to TNF, leading to a maximal response of monocytes and macrophages, which exacerbate the inflammation (Park et al., 2017) . Therefore, the timing of IFN-I therapy is of great importance to COVID-19 treatment.

In addition to the time of treatment onset, the duration and frequency of treatment with IFN-I are also questions that must be answered. Preclinical studies on influenza viruses showed that long-term treatment with IFN-I delays the regeneration of lung epithelial cells (Major et al., 2020) . Moreover, persistent signaling of IFN-I and IFN-III may disrupt the proliferation and repair of lung epithelial cells by inducing P53 protein (Major et al., 2020) . Based on the therapeutic protocols of clinical trials, the frequency of IFN-I administration is usually 2-3 J o u r n a l P r e -p r o o f times every week that can be reduced to once a week or once every ten days using PEGylated forms of IFN-I, which has a prolonged half-life (Schreiber, 2020) . showed that there was a significant difference between IFN-β1b and the control group in the case of Time to Clinical Improvement (TTCI) (p-value=0.031), while no significant difference was found between IFN-β1b and the control group (p-value=0.395). Also, both IFN-βs could relatively improve the clinical responses and reduce the mortality rate from 45% in the control group to 20% in the IFN-β1a group and 30% in the IFN-β1b group but the observed differences were not statistically significant (p-value=0.231) (Darazam et al., 2021) . The results of this study suggest that IFN-β1a might be a more reasonable choice than IFN-β1b for the management of COVID-19 due to a significant reduction in TTCI that was observed using IFN-β1a (Darazam et al., 2021) . Surprisingly, although they showed that the treatment efficacy was higher in the early stages than the advanced stages of the disease, serious adverse effects following IFN-I therapy were not observed even in the advanced J o u r n a l P r e -p r o o f stages of COVID-19 (Darazam et al., 2021) . Despite all the aforementioned studies, the lack of multi-arm multi-stage (MAMS) clinical trials to compare the safety and efficacy of IFN-I in the prevention and treatment of COVID-19 at different stages of the disease is still felt.

Some studies reported the presence of IFN-I neutralizing antibodies in a small proportion of COVID-19 patients, which reduced the effectiveness of IFN-I treatment . In these cases, the type of IFN-I recognized by the neutralizing antibody should be determined, and patient treatment should be performed using that type of IFN-I, preferably in anti-IFN-I neutralizing antibody-positive subjects .

Taken together, given the long experience of IFN-I therapy and the availability of the drug at an affordable price, IFN-Is could be considered potential candidates for treating COVID-19.

However, various clinical questions should be answered before to demonstrate a significant clinical benefit to COVID-19 patients.

Recently, it has been demonstrated that insufficient antiviral IFN-I responses are the hallmark of COVID-19 infection (Lin and Shen, 2020) . Several SARS-CoV-2 proteins, including nucleocapsid (N), membranous (M), and nonstructural (NS) proteins, inhibit the production of IFN-Is (Palermo et al., 2021) . On the other hand, the result of multiplexed single-cell epitope and transcriptome sequencing revealed the dysfunction of ISG responses in patients with severe COVID-19 (van der Wijst et al., 2021) . Therefore, the production of circulating autoantibodies against IFN-Is could be considered an impairment mechanism of IFN-I responses in critical COVID-19 patients .

It is reasonable to presume that the dysfunction of IFN-I development or production of autoantibodies against it may result in viral spread, subsequent pulmonary and systemic J o u r n a l P r e -p r o o f inflammation, as well as COVID-19 predisposition. As summarized in Table-1, anti-IFN-α autoantibodies were detected in patients recovered from severe COVID-19 (Acosta-Ampudia et al., 2021) . Approximately 10% of COVID-19 patients have a remarkable level of autoantibodies against IFN-I and these antibodies are associated with the severity of the infection Zhou and Wang, 2021 ).

An observational study on more than 980 patients with severe COVID-19 infection has indicated significant autoantibodies against IFN-I, especially both IFN-α2 and IFN-ω (13.7%) compared with unexposed healthy individuals (0.3%) .

Additionally, a large cohort study in COVID-19 infected patients revealed that 3.5% of these patients harbored some mutations in those eight genes involved in coding the TLR signaling molecules and the IFN-I pathway . . In this study, anti-IFN-α2 autoantibodies with neutralizing activity were detected in 15 of the mentioned patients, which made a significant impairment of the IFN-I response . In another study;

among 47 patients with severe COVID-19 pneumonia who were hospitalized in Madrid, Spain; more than 10% showed IFN-α and IFN-ω neutralizing autoantibodies compared to asymptomatic control subjects. These autoantibodies were significantly associated with higher CRP levels and lower lymphocyte counts and increased risk of death in patients (Troya et al., 2021) . Hence, patients with anti-IFN-I neutralizing autoantibodies might be considered more susceptible to COVID-19 infection (Gupta et al., 2020) .

According 

Pieces of evidence suggested that the presence of autoantibodies against IFN makes patients vulnerable to the severity of COVID-19. As a result, measurement of the autoantibody levels in patients may help us choose the best treatment protocol and manage the disease more intelligently (Khamsi, 2021) .

Several treatment strategies including plasma exchange through plasmapheresis, depletion of plasmablasts by monoclonal antibodies, preventing auto-antibody production, administration of convalescent plasma, recombinant IFN-I, corticosteroids, and intravenous immunoglobulin (IVIG) have been suggested for the management of these autoantibodies in patients with COVID-19. However, still, there is not sufficient data regarding the application of these therapeutic tactics (Casadevall and Pirofski, 2020) .

Convalescent plasma is a transfusion method based on passive immunization. In this method, infected patients receive plasma from donors recovered from COVID infection (Selvi, 2020) .

Early administration of convalescent plasma can decrease the severity of the symptoms (Acosta-Ampudia et al., 2021) . Several studies showed that this transfusion has no critical adverse effects on recipients, and they also showed a temporary increase in IgG levels against SARS-CoV-2, which improved symptoms of the disease during 1-3 days after transfusion Generally, before subcutaneous injection of IFN-I, plasmapheresis is performed to remove autoantibodies and to prevent neutralization of recombinant IFN-I in patients. It was shown that treatment with IFN-I could be effective during the initial phase of COVID-19, while its administration can be lethal when patients` conditions worsen, probably due to cytokine storm and systemic inflammation (Bojdani et al., 2020) . A preliminary study by Monk et al. revealed that inhalation of IFN-β can improve the clinical outcomes of COVID-19 patients (Monk et al., 2021) . In a cohort study by Troya et al. on 47 patients with severe COVID-19 infection, approximately 10.6% had significantly high levels of autoantibodies against IFN-1α and IFN-ω, while no anti-IFN-β antibody was detected in their plasma samples. They were treated with recombinant IFN-β1b, and there were no significant clinical differences between patients with or without autoantibodies in their response to IFN-β1b therapy (Troya et al., 2021) .

IVIG can regulate the immune system response to SARS-COV-2 by blocking proinflammatory cytokines such as IL-1, IL-6, and TNF-α, inhibition of Th1 and Th17 cells, neutralization of autoantibodies, and expansion of regulatory T cells (Maddur et al., 2014; Mendoza-Pinto et al., 2021) . However, according to the results of IVIG usage in the SARS-

CoV-1 outbreak in 2003, IVIG administration can lead to undesirable reactions such as developing venous thromboembolism, which was seen despite using heparin in SARS-CoV-1 patients (Lew et al., 2003) .

Plasmablast depletion therapy and inhibition of reactive B-cells through several mechanisms result in the elimination of B-cells harboring inborn abnormality by targeting CD19, CD20, and B-cell activating factor (BAFF), which will prevent the production of autoantibodies. These procedures are used to control autoimmune disorders, including SLE . These are only some suggestions for future studies, based on plasmablast depletion as currently, there is no registered investigation on this idea.

It is now obvious that IFN-Is play an important role in the battle between the immune system and SARS-COV-2. Although SARS-COV-2 is highly sensitive to IFN-Is, its inhibitory Finally, to overcome defective functions of IFN-Is, we can also explore approaches to induce the production of functional IFN-Is in the patient's body or to find some solutions to protect IFN-Is from undesirable effects of SARS-COV-2.

This study was conducted and supported by the Iran University of Medical Sciences, Tehran, Iran.

This study did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

All authors participated equally in data gathering, writing, revising of the article. Hossein

Khorramdelazad designed pictures.

There is no conflict of interest to declare. IRF, IFN-regulatory factor; Alt-IRF, IRFs other than IRF3 or IRF7; NF-κB, nuclear factor-κB; AP-1, activator protein 1; STING, stimulator of IFN genes; ER, endoplasmic reticulum; TYK2, tyrosine kinase 2; JAK1, Janus Kinase 1; GAS, γ-activated sequence. RLRs leads to the activation of TLR3 or RLRs, which finally induce IFN production. The secreted IFN affects the cell through a paracrine or autocrine regulation and stimulates the expression of ISGs.

An ISG, either OAS or PKR, activates RNase L via 2′, 5′-oligoadenylate synthetase or phosphorylation of eIF2, resulting in RNA degradation or translational suppression. The IFN response inhibits viral replication and damage to the cell. IFN, interferon;

LGP2, laboratory of genetics and physiology 2; MDA5, melanoma differentiation-associated gene 5; TLR3, toll-like receptor 3;

RLRs, retinoic acid-inducible gene I (RIG-I)-like receptors; ISGs, FN-stimulated genes; OAS, oligoadenylate synthetase; PKR, protein kinase R; eIF2-α, eukaryotic translation initiation factor 2α;

IFNR, interferon receptor. (Bastard et al., 2021a) 

The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19

COVID-19 convalescent plasma composition and immunological effects in severe patients

Sources of Type I interferons in infectious immunity: plasmacytoid dendritic cells not always in the driver's seat

Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry

Are we fully exploiting type I Interferons in today's fight against COVID-19 pandemic?

IFITM-Family Proteins: The Cell's First Line of Antiviral Defense

Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Lowdose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium

SARS-CoV-2 Infection Boosts MX1

Antiviral Effector in COVID-19 Patients. iScience 23, 101585

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

COVID-19 pandemic: impact on psychiatric care in the United States

The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus

Type I IFN family members: similarity, differences and interaction

In fatal COVID-19, the immune response can control the virus but kill the patient

Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls: Treasure Island

New insights into the role of RNase L in innate immunity

New-onset IgG autoantibodies in hospitalized patients with COVID-19

Tyrosine phosphorylation in Toll-like receptor signaling

Antagonism of dsRNA-Induced Innate Immune Pathways by NS4a and NS4b Accessory Proteins during MERS Coronavirus Infection

Type I interferons in host defence and inflammatory diseases. Lupus science & medicine 6, e000336

Circulating Type I Interferon Levels and COVID-19 Severity: A Systematic Review and Meta-Analysis

Structural insights into the interaction of coronavirus papain-like proteases and interferonstimulated gene product 15 from different species

Immunopathogenesis of coronavirus infections: implications for SARS

Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial

A Randomized Clinical Trial of the Efficacy and Safety of Interferon beta-1a in Treatment of Severe COVID-19

The type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases

Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia

Are Iranian sulfur mustard gas-exposed survivors more vulnerable to SARS-CoV-2? Some similarity in their pathogenesis

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

Antibodies against type I interferon: detection and association with severe clinical outcome in COVID-19 patients

Cytosolic sensing of viruses

Association between anti-interferonalpha autoantibodies and COVID-19 in systemic lupus erythematosus

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population

Enhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosis

Viral membrane fusion

Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers

SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells

Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

Regulation of type I interferon responses

Peginterferon Lambda-1a for treatment of J o u r n a l P r e -p r o o f outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Rogue antibodies could be driving severe COVID-19

Immunopathological similarities between COVID-19 and influenza: Investigating the consequences of Co-infection

Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response

Interferon beta-1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial

Severe acute respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant to its antiviral activity

The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses

B cell depletion therapies in autoimmune disease: advances and mechanistic insights

The type I interferon response in COVID-19: implications for treatment

Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome

SARS-CoV-2 induces doublestranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes

Type I interferon: From innate response to treatment for COVID-19

Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression

SARS-CoV-2 is sensitive to type I interferon pretreatment

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients

Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide

2020. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection

Antiviral activities of type I interferons to SARS-CoV-2 infection

Rationale for COVID-19 treatment by nebulized interferon-β-1b-Literature review and personal preliminary experience

Type I interferons in infectious disease

Therapeutic options for the management of severe COVID-19: A rheumatology perspective

An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area

Inhibition of respiratory virus infection by locally applied interferon

The SARS Coronavirus 3a protein causes endoplasmic reticulum stress and induces ligand-independent downregulation of the type 1 interferon receptor

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize interferon signaling

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial

TLR signalling and activation of IRFs: revisiting old friends from the NF-κB pathway

Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection

Waves of COVID-19 pandemic. Detection and SIR simulations. medRxiv

Fueling Type I Interferonopathies: Regulation and Function of Type I Interferon Antiviral Responses

Immune sensing of DNA

Type I interferons and the cytokine TNF cooperatively reprogram the macrophage epigenome to promote inflammatory activation

Interferons, interferon-like cytokines, and their receptors

Mechanisms of type-I-and type-II-interferon-mediated signalling

IFITM proteins promote SARS-CoV-2 infection and are targets for virus inhibition in vitro

Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans

Use of peginterferon alfa-2a (40 KD)(Pegasys®) for the treatment of hepatitis C. Advanced drug delivery reviews

Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications

Antiviral actions of interferons

Interferon-stimulated genes: a complex web of host defenses

The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19

Convalescent plasma: A challenging tool to treat COVID-19 patients-A lesson from the past and new perspectives

The use of nebulized pharmacotherapies during the COVID-19 pandemic

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

The role of type I interferon in the treatment of COVID-19

Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19

Patients Admitted to Intensive Care in Barcelona

Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils

A new mechanism of interferon's antiviral action: Induction of autophagy, essential for paramyxovirus replication, is inhibited by the interferon stimulated gene, TDRD7

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

Interferon response induced by Toll-like receptor signaling

The IRF family transcription factors in immunity and oncogenesis

Type I interferons in viral control and immune regulation. Current opinion in virology 16

Middle East Respiratory Syndrome Coronavirus NS4b Protein Inhibits Host RNase L Activation

Delivery of interferon-beta to the monkey nervous system following intranasal administration

Type I interferon: friend or foe?

Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, Spain

Interferon-inducible protein Mx1 inhibits influenza virus by interfering with functional viral ribonucleoprotein complex assembly

The Role of Structure in the

Diverse functional autoantibodies in patients with COVID-19

Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

The Polybasic Cleavage Site in SARS-CoV-2 Spike Modulates Viral Sensitivity to Type I Interferon and IFITM2

IFITM proteins inhibit entry driven by the MERScoronavirus spike protein: evidence for cholesterol-independent mechanisms

Interferon action-sequence specificity of the ppp (A2′ p) n A-dependent ribonuclease

Evasion of Type I Interferon by SARS-CoV-2

Protein kinase R and the inflammasome

Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity

Interferon-Inducible Myxovirus Resistance Proteins: Potential Biomarkers for Differentiating Viral from Bacterial Infections

Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation

Interferon induction of IFITM proteins promotes infection by human coronavirus OC43

Auto-antibodies against type I IFNs are associated with severe COVID-19 pneumonia

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

J o u r n a l P r e -p r o o f